[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

55

1 envelopes and vaccines alone.
2 The next part I'm going to talk about is
3 its use as a boost after live virus priming, and I'll
4 come back to that, again in HIV seronegatives, and
5 then come back to the data on the HIV seropositives
6 and give as much as one person can in overview and, I
7 hope, as much as one person can give you, as balanced
8 a presentation of the data as it's available.
9 So if we can have the first slide. I
10 really don't want you to take off the top of that,
11 because I don't have mine numbered like Fred did. So
12 flip it over. You know that he was a former chief
13 resident. It's a long skill that we've all learned.
14 I did it for Fred. I didn't have the smarts to do it
15 for myself. Okay.
16 First to emphasize HIV seronegative
17 subjects. Next slide. There have been two Phase I
18 trials conducted by the AIDS vaccine evaluation unit
19 using a variety of dosages of gp-160 made by
20 MicroGeneSys, baculovirus derived.
21 I'm going to talk about mainly its
22 relationship as it relates to the two functional
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]